Inmune Bio Files 8-K: Material Agreement & Exhibits
Ticker: INMB · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1711754
| Field | Detail |
|---|---|
| Company | Inmune Bio, Inc. (INMB) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2025 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $65,000,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing, exhibits
Related Tickers: INMB
TL;DR
INMB filed an 8-K on 12/19/25 for a material agreement and exhibits.
AI Summary
On December 19, 2025, Inmune Bio, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements and exhibits. The company, incorporated in Nevada, is involved in the biological products sector.
Why It Matters
This 8-K filing signals a significant development for Inmune Bio, Inc., potentially involving a new contract or partnership that could impact its future operations and financial standing.
Risk Assessment
Risk Level: medium — 8-K filings often disclose material events, which can introduce uncertainty or opportunity, thus warranting a medium risk assessment until the details of the agreement are fully understood.
Key Numbers
- 001-38793 — SEC File Number (Identifies the company's filing with the SEC.)
- 47-5205835 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- Inmune Bio, Inc. (company) — Registrant
- December 19, 2025 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432 (address) — Principal Executive Offices
FAQ
What is the nature of the material definitive agreement entered into by Inmune Bio, Inc.?
The filing does not specify the exact nature of the material definitive agreement, only that one was entered into on or before December 19, 2025.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on December 19, 2025.
Where is Inmune Bio, Inc. incorporated?
Inmune Bio, Inc. is incorporated in Nevada.
What is the principal executive office address for Inmune Bio, Inc.?
The principal executive office address is 225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432.
What are the main items reported in this 8-K filing?
This 8-K filing reports an entry into a material definitive agreement and includes financial statements and exhibits.
Filing Stats: 852 words · 3 min read · ~3 pages · Grade level 8.5 · Accepted 2025-12-19 16:30:33
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per shares INMB The NASDAQ Stock Ma
- $65,000,000 — rom time to time, through A.G.P., up to $65,000,000 of shares of its common stock, par valu
Filing Documents
- ea0269963-8k_inmune.htm (8-K) — 27KB
- ea026996301ex1-1_inmune.htm (EX-1.1) — 221KB
- ea026996301ex5-1_inmune.htm (EX-5.1) — 13KB
- ex5-1_001.jpg (GRAPHIC) — 15KB
- 0001213900-25-123880.txt ( ) — 509KB
- inmb-20251219.xsd (EX-101.SCH) — 3KB
- inmb-20251219_lab.xml (EX-101.LAB) — 33KB
- inmb-20251219_pre.xml (EX-101.PRE) — 22KB
- ea0269963-8k_inmune_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INMUNE BIO INC. Date: December 19, 2025 By: /s/ David Moss David Moss Chief Executive Officer 2